Overexpression of the Ets-1 transcription factor in human breast cancer
暂无分享,去创建一个
M. Duffy | E. McDermott | N. O’higgins | Y. Buggy | T. Maguire | G. McGreal | A. Hill | M J Duffy | A D K Hill | N O'Higgins | Y Buggy | T M Maguire | E McDermott | G McGreal | G. Mcgreal
[1] Y. Okada,et al. Ets-1 positively regulates expression of urokinase-type plasminogen activator (uPA) and invasiveness of astrocytic tumors. , 1999, Journal of neuropathology and experimental neurology.
[2] B. Wasylyk,et al. The Ets family of transcription factors. , 1993, European journal of biochemistry.
[3] M. Duffy,et al. Urokinase‐plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report , 1988, Cancer.
[4] S. Yamashita,et al. Overexpression of Ets-1 transcription factor in angiosarcoma of the skin. , 2000, Pathology, research and practice.
[5] P. Chomczyński,et al. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.
[6] N. Bhat,et al. Human ETS1 oncoprotein. Purification, isoforms, -SH modification, and DNA sequence-specific binding. , 1992, The Journal of biological chemistry.
[7] G. Clark,et al. Amplification of c-erbB-2 and aggressive human breast tumors? , 1988, Science.
[8] V. Sementchenko,et al. Ets target genes: past, present and future , 2000, Oncogene.
[9] N. Brünner,et al. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. , 2000, Cancer research.
[10] C. Sweep,et al. Expression of the transcription factor Ets-1 is an independent prognostic marker for relapse-free survival in breast cancer , 2002, Oncogene.
[11] A. Nordheim,et al. Gene regulation by Ets proteins. , 1993, Biochimica et biophysica acta.
[12] R. Fisher,et al. Structural inferences of the ETS1 DNA-binding domain determined by mutational analysis. , 1994, Oncogene.
[13] D. Watson,et al. Molecular analysis of the ets genes and their products. , 1990, Critical reviews in oncogenesis.
[14] K. Fujikawa,et al. The Ets‐1 and Ets‐2 transcription factors activate the promoters for invasion‐associated urokinase and collagenase genes in response to epidermal growth factor , 1998, International journal of cancer.
[15] C. Brinckerhoff,et al. ETS sites in the promoters of the matrix metalloproteinases collagenase (MMP-1) and stromelysin (MMP-3) are auxiliary elements that regulate basal and phorbol-induced transcription. , 1997, Connective tissue research.
[16] T. Noumi,et al. Ets-related protein E1A-F can activate three different matrix metalloproteinase gene promoters. , 1995, Oncogene.
[17] W Godolphin,et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.
[18] M. Duffy,et al. Studies on oestrogen receptor-alpha and -beta mRNA in breast cancer. , 2001, European journal of cancer.
[19] N. Brünner,et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. , 2002, Journal of the National Cancer Institute.
[20] J. Nesland,et al. Ets-1 messenger RNA expression is a novel marker of poor survival in ovarian carcinoma. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[21] R. Muschel,et al. Transcriptional activation of the matrix metalloproteinase-9 gene in an H-ras and v-myc transformed rat embryo cell line , 1997, Oncogene.
[22] T. Nakayama,et al. Expression of the ets-1 Proto-Oncogene in Human Colorectal Carcinoma , 2001, Modern Pathology.
[23] B. Vandenbunder,et al. Does the transcription factor c-ets1 take part in the regulation of angiogenesis and tumor invasion? , 1994, Folia biologica.
[24] S. Galiègue‐Zouitina,et al. Quantitative and qualitative variation of ETS-1 transcripts in hematologic malignancies. , 1993, Leukemia.
[25] J. Ghysdael,et al. Identification of a Ets1 variant protein unaffected in its chromatin and in vitro DNA binding capacities by T cell antigen receptor triggering and intracellular calcium rises. , 1990, Oncogene.
[26] A. Wellmann,et al. The Ets‐1 transcription factor is up‐regulated together with MMP 1 and MMP 9 in the stroma of pre‐invasive breast cancer , 2001, The Journal of pathology.
[27] N. Bhat,et al. Pleiotropic functions of ETS-1 (Review). , 1996, International journal of oncology.
[28] S. Shibata,et al. Ets-1 transcription factor-mediated urokinase-type plasminogen activator expression and invasion in glioma cells stimulated by serum and basic fibroblast growth factors. , 1999, Laboratory investigation; a journal of technical methods and pathology.
[29] M. Duffy,et al. Studies on oestrogen receptor-α and -β mRNA in breast cancer , 2001 .
[30] B. Wasylyk,et al. Ets transcription factors: nuclear effectors of the Ras-MAP-kinase signaling pathway. , 1998, Trends in biochemical sciences.
[31] S. Nakamura,et al. Immunohistochemical expression of Ets‐1 transcription factor and the urokinase‐type plasminogen activator is correlated with the malignant and invasive potential in meningiomas , 2000, Cancer.
[32] B. Vandenbunder,et al. Expression of the transcription factor c-Ets1 correlates with the occurrence of invasive processes during normal and pathological development. , 1994, Invasion & metastasis.
[33] V. Gouyer,et al. Expression of c-ets-1, collagenase 1, and urokinase-type plasminogen activator genes in lung carcinomas. , 1995, The American journal of pathology.
[34] I. Kola,et al. Regulation of gene expression by transcription factors Ets‐1 and Ets‐2 , 1994, Molecular reproduction and development.
[35] R. Li,et al. The p42 variant of ETS1 protein rescues defective Fas-induced apoptosis in colon carcinoma cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[36] M. Duffy,et al. Urokinase Plasminogen Activator: a Prognostic Marker in Breast Cancer including Patients with Axillary Node-negative Disease Materials and Methods Methods Enzymes and Protein Markers , 1997 .
[37] W. McGuire,et al. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. , 1992, Human pathology.
[38] G. Mavrothalassitis,et al. The human ETS1 gene: genomic structure, promoter characterization and alternative splicing. , 1991, Oncogene.
[39] N. Bhat,et al. The ets family of genes: molecular biology and functional implications. , 1989, Current topics in microbiology and immunology.
[40] N. Bhat,et al. Isoforms of the human ets-1 protein: generation by alternative splicing and differential phosphorylation. , 1990, Oncogene.
[41] E. Remmers,et al. Corticotropin-releasing hormone in synovial fluids and tissues of patients with rheumatoid arthritis and osteoarthritis. , 1993, Journal of immunology.
[42] B. Vandenbunder,et al. Stromal expression of c-Ets1 transcription factor correlates with tumor invasion. , 1994, Cancer research.
[43] W. Muller,et al. The pea3 subfamily ets genes are required for HER2/Neu-mediated mammary oncogenesis , 2001, Current Biology.
[44] K. Tanaka,et al. Signal transduction and transcriptional regulation of angiogenesis. , 2000, Advances in experimental medicine and biology.
[45] C. Benz,et al. Targeting the Ets Binding Site of the HER2/neuPromoter with Pyrrole-Imidazole Polyamides* , 2000, The Journal of Biological Chemistry.